These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 25023322)

  • 21. Acid-induced aggregation of human monoclonal IgG1 and IgG2: molecular mechanism and the effect of solution composition.
    Hari SB; Lau H; Razinkov VI; Chen S; Latypov RF
    Biochemistry; 2010 Nov; 49(43):9328-38. PubMed ID: 20843079
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predicting accelerated aggregation rates for monoclonal antibody formulations, and challenges for low-temperature predictions.
    Brummitt RK; Nesta DP; Roberts CJ
    J Pharm Sci; 2011 Oct; 100(10):4234-43. PubMed ID: 21671226
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Application of a high-throughput relative chemical stability assay to screen therapeutic protein formulations by assessment of conformational stability and correlation to aggregation propensity.
    Rizzo JM; Shi S; Li Y; Semple A; Esposito JJ; Yu S; Richardson D; Antochshuk V; Shameem M
    J Pharm Sci; 2015 May; 104(5):1632-40. PubMed ID: 25757872
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of a dual-wavelength size exclusion HPLC method with improved sensitivity to detect protein aggregates and its use to better characterize degradation pathways of an IgG1 monoclonal antibody.
    Bond MD; Panek ME; Zhang Z; Wang D; Mehndiratta P; Zhao H; Gunton K; Ni A; Nedved ML; Burman S; Volkin DB
    J Pharm Sci; 2010 Jun; 99(6):2582-97. PubMed ID: 20039394
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of pH on heat-induced aggregation and degradation of therapeutic monoclonal antibodies.
    Ishikawa T; Ito T; Endo R; Nakagawa K; Sawa E; Wakamatsu K
    Biol Pharm Bull; 2010; 33(8):1413-7. PubMed ID: 20686240
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Formulation development of antibodies using robotic system and high-throughput laboratory (HTL).
    Zhao H; Graf O; Milovic N; Luan X; Bluemel M; Smolny M; Forrer K
    J Pharm Sci; 2010 May; 99(5):2279-94. PubMed ID: 20014026
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimization of a platform process operating space for a monoclonal antibody susceptible to reversible and irreversible aggregation using a solution stability screening approach.
    Man A; Luo H; Levitskaya SV; Macapagal N; Newell KJ
    J Chromatogr A; 2019 Jul; 1597():100-108. PubMed ID: 30922716
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Temperature-ramped studies on the aggregation, unfolding, and interaction of a therapeutic monoclonal antibody.
    Menzen T; Friess W
    J Pharm Sci; 2014 Feb; 103(2):445-55. PubMed ID: 24382634
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The ReFOLD assay for protein formulation studies and prediction of protein aggregation during long-term storage.
    Svilenov H; Winter G
    Eur J Pharm Biopharm; 2019 Apr; 137():131-139. PubMed ID: 30818009
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relevant shaking stress conditions for antibody preformulation development.
    Eppler A; Weigandt M; Hanefeld A; Bunjes H
    Eur J Pharm Biopharm; 2010 Feb; 74(2):139-47. PubMed ID: 19922795
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improved Stability of a Model IgG3 by DoE-Based Evaluation of Buffer Formulations.
    Chavez BK; Agarabi CD; Read EK; Boyne MT; Khan MA; Brorson KA
    Biomed Res Int; 2016; 2016():2074149. PubMed ID: 27042659
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Matching pH values for antibody stabilization and crystallization suggest rationale for accelerated development of biotherapeutic drugs.
    Sjuts H; Schreuder H; Engel CK; Bussemer T; Gokarn Y
    Drug Dev Res; 2020 May; 81(3):329-337. PubMed ID: 31758731
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of formulation variables on protein stability and integrity of a model IgG4 monoclonal antibody and translation to formulation of a model ScFv.
    Gourbatsi E; Povey JF; Smales CM
    Biotechnol Lett; 2018 Jan; 40(1):33-46. PubMed ID: 28939995
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Poly(ethylene glycol)-based monolithic capillary columns for hydrophobic interaction chromatography of immunoglobulin G subclasses and variants.
    Desire CT; Arrua RD; Talebi M; Lacher NA; Hilder EF
    J Sep Sci; 2013 Sep; 36(17):2782-92. PubMed ID: 23813673
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improved Fluorescence Methods for High-Throughput Protein Formulation Screening.
    Wei Y; Larson NR; Angalakurthi SK; Russell Middaugh C
    SLAS Technol; 2018 Dec; 23(6):516-528. PubMed ID: 29884102
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High Throughput Differential Scanning Fluorimetry (DSF) Formulation Screening with Complementary Dyes to Assess Protein Unfolding and Aggregation in Presence of Surfactants.
    McClure SM; Ahl PL; Blue JT
    Pharm Res; 2018 Mar; 35(4):81. PubMed ID: 29508082
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of high-throughput biophysical methods to identify stabilizing excipients for a model IgG2 monoclonal antibody: conformational stability and kinetic aggregation measurements.
    Cheng W; Joshi SB; He F; Brems DN; He B; Kerwin BA; Volkin DB; Middaugh CR
    J Pharm Sci; 2012 May; 101(5):1701-20. PubMed ID: 22323186
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Remediating agitation-induced antibody aggregation by eradicating exposed hydrophobic motifs.
    Clark RH; Latypov RF; De Imus C; Carter J; Wilson Z; Manchulenko K; Brown ME; Ketchem RR
    MAbs; 2014; 6(6):1540-50. PubMed ID: 25484048
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quality by design: impact of formulation variables and their interactions on quality attributes of a lyophilized monoclonal antibody.
    Awotwe-Otoo D; Agarabi C; Wu GK; Casey E; Read E; Lute S; Brorson KA; Khan MA; Shah RB
    Int J Pharm; 2012 Nov; 438(1-2):167-75. PubMed ID: 22944306
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Nanoparticle-Based Assay To Evaluate Surface-Induced Antibody Instability.
    Kopp MRG; Capasso Palmiero U; Arosio P
    Mol Pharm; 2020 Mar; 17(3):909-918. PubMed ID: 31917582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.